BIOPHYTIS.jpg
BIOPHYTIS: Full results of SARA-PK study confirm Sarconeos’ good pharmacokinetic profile in elderly patients
March 02, 2017 08:00 ET | BIOPHYTIS SA
PARIS, March 02, 2017 (GLOBE NEWSWIRE) -- BIOPHYTIS (Alternext Paris:ALBPS), a biotechnology company specializing in the development of drug candidates to treat diseases of ageing, announces today...
BIOPHYTIS.jpg
BIOPHYTIS Announces Successful Completion of SARA-PK Clinical Study for Sarconeos in Sarcopenia Confirming Safety Profile
November 30, 2016 08:00 ET | BIOPHYTIS SA
ROMAINVILLE, France, Nov. 30, 2016 (GLOBE NEWSWIRE) -- BIOPHYTIS (Alternext Paris:ALBPS), a biotechnology company specialized in the development of drug candidates to treat aging diseases, announces...
BIOPHYTIS.jpg
BIOPHYTIS received regulatory authorizations to conduct SARA-OBS study in sarcopenia patients
November 22, 2016 07:30 ET | BIOPHYTIS SA
ROMAINVILLE, France, Nov. 22, 2016 (GLOBE NEWSWIRE) -- BIOPHYTIS (Alternext Paris:ALBPS) a biotechnology company specialized in the development of drug candidates to treat aging diseases, announces...
BIOPHYTIS.jpg
BIOPHYTIS Presenting Four Posters on Sarconeos at 9th International Conference on Cachexia, Sarcopenia, and Muscle Wasting
November 15, 2016 07:30 ET | BIOPHYTIS SA
ROMAINVILLE, France, Nov. 15, 2016 (GLOBE NEWSWIRE) -- BIOPHYTIS (Alternext Paris:ALBPS), a biotechnology company specializing in the development of drug candidates to treat diseases of aging,...
BIOPHYTIS.jpg
BIOPHYTIS chooses Patheon to produce the clinical batches of Macuneos, its AMD drug candidate that will enter Phase 2B
October 24, 2016 07:30 ET | BIOPHYTIS SA
ROMAINVILLE, France, Oct. 24, 2016 (GLOBE NEWSWIRE) -- BIOPHYTIS (Alternext Paris:ALBPS), a biotechnology company specializing in the development of drug candidates to treat diseases of aging,...